Introduction
Infection is the second leading cause of morbidity and mortality in haemodialysis patients. Staphylococcus auyeus is the most significant pathogen, accounting for 70-96% of bacterial infections. '-3 In a prospective study, Yu et aL4 showed a decreased incidence of S. aureus infections if 5'. aureus nasal carriage was eliminated.
Until recently, only systemic therapy with either rifampicin or clindamycin reliably eradicated S. aureus nasal carriage in haemodialysis patients.' These drugs are expensive and may be associated with significant toxicity. Topical gentamicin, vancomycin, bacitracin and oral cloxacillin or tetracycline have interrupted S. aureus nasal carriage for less than 2 weeks before relapse occurred. ' Mupirocin is a new topical antimicrobial which has been reported to effectively eradicate S. aureus nasal carriage in some patient populations6a7 including haemodialysis patients. Twenty-two (32%) of 68 patients in the haemodialysis unit were identified as S. aweus nasal carriers during the 70-day surveillance study which preceded the mupirocin trial. All 22 patients were enrolled in the trial. Twelve different phage types were identified in these 22 patients. Seventeen (77%) patients were culture negative at the end of therapy. The mean time to recurrence for those negative at the end of therapy was 3.8 weeks. Ten (46%) patients remained culture negative 4 weeks post-therapy, seven (32%) at 2 months, and five (23%) at 3 months. The positive nasal carriers at 3 months included five (23% of total) failures of therapy, seven (32%) relapses and five (23%) recolonized.
Thus, similar pre-and post-therapy phage types occurred in 12 of 17 (71%) patients not cured. All pre-and post-therapy S. aweus isolates were susceptible to mupirocin. The single subject with a pre-treatment methicillin-resistant S. aweus isolated was a treatment failure.
Therapy was well tolerated. Three (13%) of 22 patients complained of mild nasal itching. Although one of these patients missed three doses, the course of therapy was subsequently completed. An additional patient missed four doses for unknown reasons. Staphylococcus aweus nasal carriage recurred in both of these patients, one as a relapse, and one recolonized.
None of the 17 patients who were culture negative at completion of therapy developed S. aweus infections during the three months follow-up. Staphylococcus aureus cellulitis was observed, however, in two (40%) of five patients who failed therapy (P = 0.05). Ten (22%) of 46 patients not enrolled in the study but followed concurrently had S. aweus infection (P = O-03). Th ese 10 infections included three fistula site infections, three episodes of sepsis, two pneumonias, and one each of cellulitis and soft tissue infection.
Discussion
These observations contrast with the report of Chow & Yu' who found less than 25% of patients using topical agents such as gentamicin, vancomycin or bacitracin remained culture negative 3-14 days after completing treatment.
Our results are, however, similar to the observed response to systemic therapy. Yu et al. 4 found 75% of patients remained culture negative after combined therapy with oral rifampicin and topical bacitracin 1 month after therapy, but most patients had positive nasal cultures for S. aweus by 3 months after therapy. Boelaert et aZ.' have also recently reported that continuously administered mupirocin eradicated S. aweus nasal carriage in haemodialysis patients and was associated with a decreased incidence of S. aweus infections.
Although they reported no mupirocin resistance, the continual administration of drugs would likely increase the potential for resistance to develop. Our study suggests that the intermittent use of mupirocin may also be effective in eradicating S. aweus carriage in haemodialysis and is associated with a significant decrease in S. aweus infections.
We observed a higher relapse rate and lower recolonization rate than was observed in a study using a S-day course of mupirocin to eradicate chronic S. aweus nasal carriage in a group of 32 healthy subjects. Casewell & Hill6 found 10 (71%) of 14 patients recolonized and four (29%) relapsed during 22 weeks of follow-up.
These authors postulated that patients who relapsed were colonized with S. aweus at other sites. This hypothesis may explain why our patients had a higher rate of relapse. Compared to healthy controls, haemodialysis patients have twice the rate of S. aweus skin colonization.14-16 Staphylococcus aweus skin colonization has recently been correlated with personal hygiene in haemodialysis patients.r7 As this study did not include any evaluation of personal hygiene, it is not known whether the patients who failed had poorer personal hygiene. The level of personal hygiene may be relevant to the two patients who developed S. aweus infections after failing to eliminate S. aweus nasal carriage.
This preliminary information suggests that a prospective, randomized placebo-controlled trial to determine efficacy and cost benefit of mupirocin in this population is warranted. 
